Therefore, we aim to predict improved prognosis in BRAF V600E-positive CRC cells by combining Wnt inhibitors and epigenetic modifiers, specifically DNA methyltransferase (DNMT) inhibitors, alongside BRAF inhibitors, while investigating the associated factors. Here, BRAF is linked to colorectal carcinoma.